26/08/2026
Back to all articles
The CDMO industry is entering one of the most transformative periods in its history.
What many initially viewed as temporary disruptions have now become structural shifts. The combination of GLP-1 driven demand, geopolitical realignment, and aggressive consolidation is reshaping how pharmaceutical companies select manufacturing partners and how CDMOs position themselves for growth.
The message is clear:
The winners of the next decade will not be the biggest manufacturers. They will be the most strategic ecosystems.
1. The GLP-1 Effect Is No Longer a Trend. It Is an Industry Transformation.
The extraordinary success of obesity and diabetes therapies has fundamentally altered demand patterns across pharmaceutical manufacturing.
What began with semaglutide and tirzepatide has evolved into a broader peptide revolution. CDMOs worldwide are investing billions into peptide manufacturing infrastructure, yet capacity remains constrained as demand continues to outpace supply. Major players including Lonza, Bachem, PolyPeptide and Thermo Fisher are aggressively expanding capabilities. [peptidestaff.com], [dcatvci.org]
For executives, this is more than a manufacturing challenge.
It is a strategic question:
Who will secure enough capacity to support the next generation of metabolic, cardiovascular and peptide-based therapies?
Access to manufacturing capacity is becoming as valuable as intellectual property itself.
2. Samsung's Move Signals the Future of the CDMO Industry
One transaction stands out above all others this year.
Samsung Biologics' announced acquisition of PolyPeptide demonstrates where the market is heading. By combining biologics, ADCs and peptide manufacturing capabilities, Samsung is building an integrated platform designed to support multiple modalities under one roof. [dcatvci.org]
This is unlikely to be the last mega-deal.
Across the industry we are witnessing a clear trend:
Large pharmaceutical companies increasingly prefer fewer strategic partners capable of supporting development, clinical supply and commercial manufacturing globally.
The era of fragmented outsourcing relationships is gradually giving way to consolidated strategic partnerships.
The question every mid-sized CDMO should be asking today is:
Do we have a defensible specialization, or do we need scale?
3. Geopolitics Has Entered the Manufacturing Boardroom
For decades, cost optimization dominated outsourcing decisions.
Today, risk mitigation is becoming equally important.
The impact of the BIOSECURE legislation and broader supply chain diversification efforts is creating one of the largest shifts in pharmaceutical manufacturing networks seen in years. Sponsors are actively evaluating exposure to China and securing alternative capacity in Europe, North America, India and South Korea.
This creates a tremendous opportunity for European CDMOs.
Particularly in the DACH region, organizations with strong regulatory capabilities, technical excellence and available capacity may find themselves in an exceptionally favorable position over the coming years.
In board discussions, resilience is rapidly becoming as important as efficiency.
4. ADC Manufacturing Is Becoming a Strategic Growth Engine
Another development receiving increasing attention is the rise of antibody-drug conjugates (ADCs).
The ADC pipeline continues to expand, and with it comes a growing need for specialized manufacturing expertise, containment technologies and integrated development solutions. Many biotech companies lack the internal capabilities required for ADC production, making outsourcing essential.
The result?
CDMOs that can combine biologics production, linker technologies, payload manufacturing and fill-finish capabilities are becoming highly valuable strategic partners.
This is not simply another therapeutic category.
It represents one of the most attractive long-term growth opportunities in pharmaceutical outsourcing.